A phase 1 trial of BKM120 (Buparlisib) in combination with fulvestrant in postmenopausal women with estrogen receptor positive metastatic breast cancer

PURPOSE: This trial was conducted to determine the maximum tolerated dose (MTD) and preliminary efficacy of buparlisib, an oral pan-class I PI3K inhibitor, plus fulvestrant in postmenopausal women with metastatic estrogen receptor positive breast cancer (ER+BC). EXPERIMENTAL DESIGN: Phase IA employe...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Ma, Cynthia X., Luo, Jingqin, Naughton, Michael, Ademuyiwa, Foluso, Suresh, Rama, Griffith, Malachi, Griffith, Obi L., Skidmore, Zachary L., Spies, Nicholas C., Ramu, Avinash, Trani, Lee, Pluard, Timothy, Nagaraj, Gayathri, Thomas, Shana, Guo, Zhanfang, Hoog, Jeremy, Han, Jing, Mardis, Elaine, Lockhart, Craig, Ellis, Matthew J.
Format: Artigo
Sprog:Inglês
Udgivet: 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4818722/
https://ncbi.nlm.nih.gov/pubmed/26563128
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-15-1745
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker